英诺赛科申请H股全流通

Core Viewpoint - InnoCare Pharma (02577) has submitted an application to the China Securities Regulatory Commission (CSRC) to convert 374 million domestic unlisted shares into H-shares, aiming for listing on the Hong Kong Stock Exchange [1] Group 1 - The company submitted the application on September 29, 2025 [1] - The conversion of domestic unlisted shares into H-shares is contingent upon obtaining approvals from relevant regulatory bodies, including the CSRC and the Hong Kong Stock Exchange [1] - Upon completion of the necessary regulatory approvals and compliance with applicable laws and regulations, the shares will be eligible for trading on the main board of the Hong Kong Stock Exchange [1]